Click to watch the report overview video for a comprehensive explanation of each section of the Prolaris report.
Prolaris is a cell-cycle proliferation-based biomarker that determines how aggressive your patients cancer is behaving. Prolaris eliminates guesswork around cancer risk by combining clinical and pathological features with a personalized tumor aggressiveness score.
Click the number of each section to learn more.
Hover/tap on each section of the sample Prolaris Biopsy Report to learn more about each segment.
The Prolaris Molecular Score is calculated by measuring the expression of 31 cell cycle progression (CCP) genes in the tumor. This predicts the behavior of the tumor. The majority of Prolaris Molecular Scores fall between 1-11, with a higher score indicating more aggressive cancer.
Clinical variables and the Prolaris Molecular Score are combined to calculate a patient’s risk assessment.
Men with low Prolaris scores are identified as being safe for active surveillance and may initially be spared unnecessary treatment, significantly impacting their quality of life.
Men who are NOT considered safe for active surveillance are identified as candidates for single-modal therapy, which is defined as one therapy planned at the treatment onset.
Men who are not considered safe to pursue single-modal treatment are identified as candidates for multi-modal therapy, which is defined as either radiation with androgen deprivation or surgery with intensified therapy per guideline recommendations.
A patient’s 10-year risk of disease specific mortality when choosing Active Surveillance. See risk assessment detail page for more information.
A patient’s 10-year risk of developing metastatic cancer when choosing single-modal treatment like surgery or radiation.
A patient’s 10–year risk of metastasis when choosing Radiation Therapy AND Androgen Deprivation Therapy (ADT)
Patients with a 10-year risk of Disease Specific Mortality (DSM) within the green box are considered candidates for AS. This threshold was validated on conservatively managed patients with DSM as the primary outcome.
For a patient considering single modal treatment, the 10-year risk of metastasis is shown within the blue box. This threshold was validated on patients treated with single-modal therapy, with metastasis as the primary endpoint.
Absolute Risk Reduction is an individualized assessment of how adding hormone therapy (ADT) to Radiation Therapy (RT) may reduce a patient’s risk of metastasis over the next 10 years
The patient’s risk of Disease Specific Mortality or metastasis is represented with a person icon. This person is compared to other patients within their NCCN risk group (based on clinical parameters alone). The average DSM risk of each NCCN category is shown with a triangle. The active surveillance threshold is indicated by a dashed line The multi-modal threshold is indicated with a dotted line.
The test description and references are provided on the final page of the report.
Myriad’s UroSuite gives health care providers the ability to directly order a complete suite of tests for comprehensive insights to guide prostate cancer treatment, including:
Myriad Genetics is the only lab to offer comprehensive testing across the spectrum of prostate cancer care, along with best-in-class support and specialists for you and your patients at every step.
Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.
This casual, yet educational, podcast is committed to keeping you informed on all things urology.
Stay current with clinical validation and utility publications and more.
Find the Myriad documents and forms you need right here.
Read about the latest urology insights and advances.